Based on our data, we propose that when combined with conventional chemotherapy, such as cisplatin, circMAP3K13 or MAP3K13-232aa could improve treatment efficacy for drug-resistant patients with GC. The gene discussed is MAP3K13; the disease is gastric cancer.